Opinion

Video

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.

Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Bertram Yuh, MD, MISM, MSHCPM
2 KOLs are featured in this series.
2 KOLs are featured in this series.